LPL

Across TCGA pan-cancer cohorts, LPL mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LPL data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LPL mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LPL expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where LPL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.434	0.799	.007	18	view →
CCRCC	OS	Quartile	All	1.000	0.777	.014	17	view →
PDAC	OS	Median	All	0.261	0.449	.023	8	view →
HNSC	OS	Quartile	All	0.978	0.783	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LPL–LUAD (OS)

Open the LUAD breakdown →